<DOC>
	<DOC>NCT02289924</DOC>
	<brief_summary>The main objectives of this non-interventional cohort field study are to evaluate effectiveness of Eylea and to describe follow-up as well as treatment patterns in patients with wAMD (wet age-related macular degeneration) in routine clinical practice in Italy for a study population of "naïve" patients</brief_summary>
	<brief_title>Aflibercept (Eylea) in roUtine Clinical Practice in patientS With Wet Age-related Macular Degeneration in Italy</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Wet Macular Degeneration</mesh_term>
	<criteria>"Naïve" patients with wet AMD(agerelated macular degeneration) treated with Eylea (in accordance with the local Summary of Product Characteristics, SPC). Exclusion criteria as listed in the local SPC. Scar, fibrosis, or atrophy involving the center of the fovea in the study eye. Any concomitant therapy with another agent to treat wet AMD in the study eye. Any prior or concomitant therapy with another drug for wAMD.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>wet AMD</keyword>
</DOC>